Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1985 3
1986 1
1987 5
1989 2
1991 1
1992 2
1993 4
1994 3
1995 6
1996 4
1997 2
1998 6
1999 5
2000 2
2001 3
2002 9
2003 6
2004 2
2005 7
2006 5
2007 6
2008 3
2009 9
2010 8
2011 5
2012 8
2013 9
2014 7
2015 12
2016 12
2017 9
2018 15
2019 7
2020 6
2021 8
2022 5
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Pignon JM, Braun T, Marolleau JP, Cahn JY, Chalandon Y, Lhéritier V, Beldjord K, Béné MC, Ifrah N, Dombret H; for GRAALL. Maury S, et al. N Engl J Med. 2016 Sep 15;375(11):1044-53. doi: 10.1056/NEJMoa1605085. N Engl J Med. 2016. PMID: 27626518 Free article. Clinical Trial.
The overall incidence rate of severe adverse events did not differ significantly between the two groups, but fewer allergic reactions to asparaginase were observed in the rituximab group. CONCLUSIONS: Adding rituximab to the ALL chemotherapy protocol improved the outcome f …
The overall incidence rate of severe adverse events did not differ significantly between the two groups, but fewer allergic reactions to asp …
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.
Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL). Huguet F, et al. J Clin Oncol. 2018 Aug 20;36(24):2514-2523. doi: 10.1200/JCO.2017.76.8192. Epub 2018 Jun 4. J Clin Oncol. 2018. PMID: 29863974 Free article. Clinical Trial.
Patients 55 years of age, in whom a lower compliance to the whole planned chemotherapy was observed, benefited significantly from hyper-C, whereas younger patients did not. Conclusion No significant benefit was associated with the introduction of a hyper-C sequence into a …
Patients 55 years of age, in whom a lower compliance to the whole planned chemotherapy was observed, benefited significantly from hyp …
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.
Bassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, Messina M, Elia L, De Propris MS, Scattolin AM, Audisio E, Marbello L, Borlenghi E, Zappasodi P, Mauro E, Martinelli G, Mattei D, Fracchiolla N, Bocchia M, De Fabritiis P, Bonifacio M, Candoni A, Cassibba V, Di Bartolomeo P, Latte G, Trappolini S, Guarini A, Vitale A, Fazi P, Piciocchi A, Rambaldi A, Foà R. Bassan R, et al. Blood Adv. 2023 Aug 22;7(16):4448-4461. doi: 10.1182/bloodadvances.2022009596. Blood Adv. 2023. PMID: 37276451 Free PMC article.

In multivariate analysis, age and MRD were independent factors predicting DFS rates of 86% (age 40 and MRD-negative), 64%-65% (MRD-positive or age > 40) and 25% (age > 40 and MRD-positive); P < .0001. Grade 2 pegaspargase toxicity was mainly observed at cou

…
In multivariate analysis, age and MRD were independent factors predicting DFS rates of 86% (age 40 and MRD-negative), 64%-65% (MRD-po …
TP53 in adult acute lymphoblastic leukemia.
Salmoiraghi S, Rambaldi A, Spinelli O. Salmoiraghi S, et al. Leuk Lymphoma. 2018 Apr;59(4):778-789. doi: 10.1080/10428194.2017.1344839. Epub 2017 Jul 6. Leuk Lymphoma. 2018. PMID: 28679301 Review.
The alterations of the oncosuppressor gene TP53, including deletions, sequence mutations and defect in its expression due to regulatory defects, define a new important predictor of adverse outcome. More recently, new drugs have been developed with the aim of targeting p53 …
The alterations of the oncosuppressor gene TP53, including deletions, sequence mutations and defect in its expression due to regulatory defe …
Clinical updates in adult acute lymphoblastic leukemia.
Al Ustwani O, Gupta N, Bakhribah H, Griffiths E, Wang E, Wetzler M. Al Ustwani O, et al. Crit Rev Oncol Hematol. 2016 Mar;99:189-99. doi: 10.1016/j.critrevonc.2015.12.007. Epub 2015 Dec 19. Crit Rev Oncol Hematol. 2016. PMID: 26777876 Review.
Finally, the advent of new immunotherapeutic approaches led us to predict that in few years, ALL therapy might be based heavily on non-chemotherapeutic approaches....
Finally, the advent of new immunotherapeutic approaches led us to predict that in few years, ALL therapy might be based heavily on no …
Advances in adult acute lymphoblastic leukemia therapy.
Aldoss I, Stein AS. Aldoss I, et al. Leuk Lymphoma. 2018 May;59(5):1033-1050. doi: 10.1080/10428194.2017.1354372. Epub 2017 Jul 26. Leuk Lymphoma. 2018. PMID: 28745565 Review.
Progress in adult acute lymphoblastic leukemia (ALL) treatment has been met with challenge until recently. ...In this review, we will discuss the most significant advances in treating adult ALL observed in the last five years that have the poten …
Progress in adult acute lymphoblastic leukemia (ALL) treatment has been met with challenge until recently. ...In …
Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience.
Ibrahim RI, Saeed AM. Ibrahim RI, et al. Asian Pac J Cancer Prev. 2022 May 1;23(5):1647-1651. doi: 10.31557/APJCP.2022.23.5.1647. Asian Pac J Cancer Prev. 2022. PMID: 35633549 Free PMC article.
Patients with complete remission and negative MRD exhibited significantly higher overall survival when compared to patients having MRD positivity (P value 0.027). CONCLUSION: MRD is a powerful predictor of outcome in ALL and its positivity at different time points is assoc …
Patients with complete remission and negative MRD exhibited significantly higher overall survival when compared to patients having MRD posit …
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia.
Gökbuget N, Ihrig K, Stadler M, Stelljes M, Elmaagacli A, Starck M, Raffel S, Stoltefuss A, Viardot A, Kreuzer KA, Heidenreich D, Renzelmann A, Wäsch R, Topp MS, Ritter B, Reimer P, Beck J, Westermann J, Wendelin K, Alakel N, Hanoun M, Serve H, Hoelzer D. Gökbuget N, et al. Haematologica. 2023 Jul 1;108(7):1758-1767. doi: 10.3324/haematol.2022.281820. Haematologica. 2023. PMID: 36779593 Free PMC article.
Cure rates in adult acute lymphoblastic leukemia (ALL) improved using pediatric-based chemotherapy and stem cell transplantation (SCT). ...SCT impacted ECOG status and comorbidity occurrence significantly. ECOG 0-1 was observed in 86% of SCT and …
Cure rates in adult acute lymphoblastic leukemia (ALL) improved using pediatric-based chemotherapy and stem cell …
Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
Ashouri K, Nittur V, Ginosyan AA, Hwang J, Adnani B, Chen D, Savitala-Damerla L, Schiff K, Chaudhary P, Kovach AE, Ladha A, Siddiqi I, Ali A, Woan K, Tam E, Yaghmour G. Ashouri K, et al. Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):e59-e66.e2. doi: 10.1016/j.clml.2023.11.002. Epub 2023 Nov 19. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38061959
INTRODUCTION: Detection of measurable residual disease (MRD) in adults with acute lymphoblastic leukemia (ALL) is a vital biomarker in risk prediction and treatment selection. Next-generation sequencing (NGS) offers greater sensitivity relative to multiparametric flow cyto …
INTRODUCTION: Detection of measurable residual disease (MRD) in adults with acute lymphoblastic leukemia (ALL) is a vital biomarker in risk …
Transplantation in adult ALL.
Goldstone AH, Rowe JM. Goldstone AH, et al. Hematology Am Soc Hematol Educ Program. 2009:593-601. doi: 10.1182/asheducation-2009.1.593. Hematology Am Soc Hematol Educ Program. 2009. PMID: 20008244 Review.
The value of the allogeneic graft-versus-leukemia effect in adult acute lymphoblastic leukemia (ALL) has now been conclusively demonstrated and confirmed. ...As in childhood ALL minimal residual disease studies may be extremely useful in predicting …
The value of the allogeneic graft-versus-leukemia effect in adult acute lymphoblastic leukemia (ALL) has now bee …
193 results